GlassScriptPhysician profile
Amal Tanagho
NPI 1154538023
$10,956.40
in general payments reported to CMS, 2019-2025
30 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $1,076 · 2021: $1,305 · 2022: $1,937 · 2023: $2,343 · 2024: $1,593 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,743.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,652.10 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $1,449.07 | 2019-2025 | Trintellix |
| Lundbeck LLC | $1,172.70 | 2019-2025 | Rexulti, Brintellix |
| Otsuka America Pharmaceutical, INC. | $997.43 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $880.77 | 2021-2025 | Caplyta |
| Bausch Health US, LLC | $702.79 | 2019-2025 | Aplenzin, Wellbutrin |
| Allergan, INC. | $616.96 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $509.00 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $343.28 | 2021-2023 | Qelbree |
| Axsome Therapeutics, INC. | $339.56 | 2022-2025 | Auvelity |
| Adlon Therapeutics L.P. | $303.95 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $296.34 | 2024-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $257.22 | 2022-2025 | Quviviq, Quviviq |
| Alkermes, INC. | $251.44 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Eisai INC. | $239.96 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $239.52 | 2022-2023 | Azstarys |
| Tris Pharma INC | $159.13 | 2019-2024 | Dyanavel Xr |
| Indivior INC. | $128.51 | 2021-2024 | Sublocade |
| Noven Therapeutics, LLC | $79.48 | 2023 | Xelstrym, Secuado |
| Janssen Pharmaceuticals, INC | $73.06 | 2019 | |
| Neos Therapeutics, LP | $69.36 | 2025 | Adzenys Xr-Odt, Exxua |
| Collegium Pharmaceutical, INC. | $36.40 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $23.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.31 | 2025 | Cobenfy |
| Sun Pharmaceutical Industries INC. | $22.91 | 2021 | |
| Almatica Pharma LLC | $22.12 | 2021 | |
| Noven Pharmaceuticals, INC. | $20.57 | 2024 | Xelstrym |
| Neurocrine Biosciences, INC. | $19.45 | 2019 | |
| Orexo US, INC. | $15.43 | 2020 | |
| Mdd US Operations, LLC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amal Tanagho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.